Nanopharm-logo-with-signature-Pantone (1)
Close this search box.

03 Dec 2020

Assessing Particle Size in DPIs with Spraytec & Unidose


This research paper delves into the evaluation of different setups to combine Spraytec and Unidose™ for assessing the particle size distribution of dry powder inhalers. The study is a significant stride in the field of respiratory drug delivery, focusing on the therapeutic effect of dry powder and the factors influencing its performance. The paper presents a detailed analysis of the impact of formulation physico-chemical and device factors on the fluidization of a static powder bed under patient air flow. It also introduces an apparatus, Unidose™, developed to capture the whole impactor sized mass (ISM) dose onto a filter for subsequent analysis in terms of microstructure, dissolution, and morphology directed Raman microscopy (MDRS). The research paper provides valuable insights into the particle size distribution of the ISM dose by laser diffraction and automated imaging, offering a comprehensive understanding of the subject matter.

Related Posts


Nanopharm Announces Exclusive Collaboration With Fluidda To Accelerate Regulatory Pathway For OINDP Using SmartTrack

Crystal Lake, Illinois, September 22, 2022 – Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar (NYSE: ATR) in 2019, as part of the company’s strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug development process.

Read More »